Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

Vertex’s research guru has warned that it could take another 15 years to produce a suite of medicines that treat all strains of the disease, saying that a deal with the NHS will be crucial to ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Meta Platforms should benefit from multiple AI tailwinds. Vertex Pharmaceuticals has two new drugs on the market, with more potentially on the way. Shopify should benefit from the switch to e ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Access Vertex stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily. Investing.com - Financial Markets Worldwide ...

Vertex Securities Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 34.86 Crore) operating in Financial Services sector. Vertex Securities Ltd. key ...